Eficacia y seguridad de vacunas contra SARS-COV-2 en pacientes con enfermedades reumatológicas autoinmunes

Abstract

Background: The coronavirus disease caused by SARS-CoV-2 was declared a pandemic, causing considerable human and economic losses. Patients with autoimmune rheumatologic diseases are at greater risk of infection by SARS-CoV-2 due to factors of the disease as well as those derived from treatment, with the development of vaccines, immunization has been prioritized in this group of patients, however, the efficacy and safety of vaccines against SARS-CoV-2 have not been studied in this population due to their exclusion in phase clinical trials II-III. Objective: To determine the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatic diseases. Methodology: A non-experimental, descriptive, bibliographic review study will be carried out on the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatic diseases, by searching for scientific articles in databases such as PubMed, Scopus and ScienceDirect published in English and Spanish from January 1, 2020 to December 1, 2022. Only those articles that have full access to their content and do not belong to gray literature were obtained, no book chapters or theses were obtained undergraduate and postgraduate. Results: The efficacy of vaccines against SARS-CoV-2 in patients with rheumatic diseases is reduced compared to the general population and the safety related to the adverse effects of vaccines is similar to those found in the general population.